ENO-1001

ENO-1001 is a pre-IND, genetically modified cell therapy being developed by Enochian BioSciences as a potentially sterilizing cure for HIV/AIDS, building on an immune-based approach that uses autologous or allogeneic immune or stem cells engineered to resist HIV infection and achieve long-term viral control without continuous antiretroviral therapy.[1][5][7][13] The program is positioned within Enochian’s HIV pipeline as its lead candidate, with corporate disclosures describing it as an innovative gene-modified cellular therapy aimed at eradicating or functionally curing HIV infection rather than simply suppressing viral replication.[5][13]